Tucotuzumab
Tucotuzumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Immunomedics.
History[edit | edit source]
Tucotuzumab was one of the many monoclonal antibodies developed for the treatment of cancer. It was developed by Immunomedics, a company that specializes in the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.
Mechanism of Action[edit | edit source]
As a monoclonal antibody, Tucotuzumab works by targeting and attaching to specific proteins on the surface of cancer cells. This allows the immune system to better recognize and attack these cells.
Clinical Trials[edit | edit source]
Tucotuzumab has undergone various clinical trials to test its effectiveness and safety in treating cancer. The results of these trials have contributed to the understanding of the drug's potential benefits and risks.
See Also[edit | edit source]
References[edit | edit source]
| Tucotuzumab Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
